Use of asthma medication during pregnancy and risk of specific congenital anomalies: A European case-malformed control study.
Hansen, Anne Vinkel
Neville, Amanda J
de Walle, Hermien
Affiliation10 Department of Public Health, Health Service Executive South, Ireland.
Local subject classificationPUBLIC HEALTH DEPARTMENT
MetadataShow full item record
CitationUse of asthma medication during pregnancy and risk of specific congenital anomalies: A European case-malformed control study. 2015: J. Allergy Clin. Immunol.
JournalThe Journal of allergy and clinical immunology
AbstractPregnant women with asthma need to take medication during pregnancy.
We sought to identify whether there is an increased risk of specific congenital anomalies after exposure to antiasthma medication in the first trimester of pregnancy.
We performed a population-based case-malformed control study testing signals identified in a literature review. Odds ratios (ORs) of exposure to the main groups of asthma medication were calculated for each of the 10 signal anomalies compared with registrations with nonchromosomal, nonsignal anomalies as control registrations. In addition, exploratory analyses were done for each nonsignal anomaly. The data set included 76,249 registrations of congenital anomalies from 13 EUROmediCAT registries.
Cleft palate (OR, 1.63; 95% CI, 1.05-2.52) and gastroschisis (OR, 1.89; 95% CI, 1.12-3.20) had significantly increased odds of exposure to first-trimester use of inhaled β2-agonists compared with nonchromosomal control registrations. Odds of exposure to salbutamol were similar. Nonsignificant ORs of exposure to inhaled β2-agonists were found for spina bifida, cleft lip, anal atresia, severe congenital heart defects in general, or tetralogy of Fallot. None of the 4 literature signals of exposure to inhaled steroids were confirmed (cleft palate, cleft lip, anal atresia, and hypospadias). Exploratory analyses found an association between renal dysplasia and exposure to the combination of long-acting β2-agonists and inhaled corticosteroids (OR, 3.95; 95% CI, 1.99-7.85).
The study confirmed increased odds of first-trimester exposure to inhaled β2-agonists for cleft palate and gastroschisis and found a potential new signal for renal dysplasia associated with combined long-acting β2-agonists and inhaled corticosteroids. Use of inhaled corticosteroids during the first trimester of pregnancy seems to be safe in relation to the risk for a range of specific major congenital anomalies.
- Risk of congenital anomalies after exposure to asthma medication in the first trimester of pregnancy - a cohort linkage study.
- Authors: Garne E, Vinkel Hansen A, Morris J, Jordan S, Klungsøyr K, Engeland A, Tucker D, Thayer DS, Davies GI, Nybo Andersen AM, Dolk H
- Issue date: 2016 Sep
- Beta-Blocker Use in Pregnancy and Risk of Specific Congenital Anomalies: A European Case-Malformed Control Study.
- Authors: Bergman JEH, Lutke LR, Gans ROB, Addor MC, Barisic I, Cavero-Carbonell C, Garne E, Gatt M, Klungsoyr K, Lelong N, Lynch C, Mokoroa O, Nelen V, Neville AJ, Pierini A, Randrianaivo H, Rissmann A, Tucker D, Wiesel A, Dolk H, Loane M, Bakker MK
- Issue date: 2018 Apr
- Beta2-agonists use during pregnancy and the risk of congenital malformations.
- Authors: Eltonsy S, Forget A, Blais L
- Issue date: 2011 Nov
- Risk of congenital malformations for asthmatic pregnant women using a long-acting β₂-agonist and inhaled corticosteroid combination versus higher-dose inhaled corticosteroid monotherapy.
- Authors: Eltonsy S, Forget A, Beauchesne MF, Blais L
- Issue date: 2015 Jan
- Controversies regarding long-acting β2-agonists.
- Authors: Khianey R, Oppenheimer J
- Issue date: 2011 Aug